Gilead Sciences, Inc. (GILD)
After hours:
| Previous Close | 66.93 |
| Open | 67.01 |
| Bid | 66.13 x 500 |
| Ask | 66.17 x 300 |
| Day's Range | 65.90 - 67.01 |
| 52 Week Range | 65.90 - 87.87 |
| Volume | |
| Avg. Volume | 7,420,538 |
| Market Cap | 82.5B |
| Beta (5Y Monthly) | 0.20 |
| PE Ratio (TTM) | 14.70 |
| EPS (TTM) | 4.50 |
| Earnings Date | Apr 25, 2024 |
| Forward Dividend & Yield | 3.08 (4.60%) |
| Ex-Dividend Date | Mar 14, 2024 |
| 1y Target Est | 79.65 |
ACCESSWIREGilead Sciences Publishes 2023 ESG Impact Report
NORTHAMPTON, MA / ACCESSWIRE / April 18, 2024 / Gilead Sciences published its 2023 Environmental, Social and Governance (ESG) Impact Report, which uses the ESG framework to highlight the successes and achievements of the prior year. In this year's ...
ZacksAnalysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PR NewswireGILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA
Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant ("Grant") to support community-backed innovative projects associated with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV). An official announcement was made at a Gilead-hosted symposium titled "Partnering for Global Health Equity: Case Studies from Around the World," held during the World Hepatitis Summit ("Summit") in Lisbon.
